Develop a rapid, efficient and low cost extracellular vesicles isolation method toward non-invasive non-small cell lung cancer molecular analysis - SUMMARY/Abstract
Cancer is one of the leading causes of death in US. It is estimated that there were about 564,800 deaths from
cancer in 2017, which was more than 1,500 people per day. The high mortality rate is a direct result of lack of
effective early stage clinical diagnosis method and therapeutic stratification. If cancer can be effective detected
early and treated with right therapy, the average five years relative survival rate would greatly increase.
Extracellular vesicles (EVs), bilayered nano-sized vesicles that are found in all bodily fluids, are emerging as a
appealing type of cancer biomarker for non-invasive cancer diagnosis and therapeutic stratification. EVs would
provide significant potential benefit for cancer patients that need repetitive tissue biopsy. For example, solid
tumors are not accessible in about 49% of advanced or metastatic non-small cell lung cancer (NSCLC) patients.
To unleash EVs’ great potential in clinical applications, rapid and efficient isolation of EVs is a prerequisite.
However, most of current EVs isolation approaches cannot meet the need in clinical settings due to inherent
shortcomings (e.g. lengthy procedure, low yield, and low throughput). Additionally, in terms of clinical application
of EV in cancer molecular analysis, there is no FDA approved EV-based diagnostic tools available. Captis
Diagnostics has developed a new proprietary lipid nanoprobe (LNP) system that can isolate EVs directly from
samples (US Application No. 62/430,161 and International Application No. PCT/US2017/064634). The LNP is
capable of efficiently isolating EVs from cell culture media or human body fluids (e.g. plasma) using a rapid
workflow and inexpensive reagents. In this proposal, we propose to develop and commercialize our lipid
nanoprobe system invention for EV isolation from plasma and further develop EV DNA analysis platform for
targeted therapy selection in NSCLC patients. For Aim 1, Captis Diagnostics will optimize and validate of the
LNP technology to develop it to a research kit for EV isolation that can achieve high EV isolation efficiency,
simple and short workflow, and adaption to complex bodily fluids samples, such as blood plasma. Aim 2 will
develop a proof-of-concept clinical assay for targeted therapy selection in NSCLC patients by combining
mutation detection by digital droplet PCR (ddPCR) with LNP EV isolation . Successful completion of these Aims
will yield a proprietary advanced technology and position Captis Diagnostics to pursue clinical validation of the
EV in clinical assay for targeted therapy selection for cancer patients. Phase II activities will be focused on the
clinical performance of NSCLC targeted therapy selection assays, in which the EV isolation technology will be
tested with samples from cancer patients to validate its clinical utility.
